You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 9, 2024

~ Buy the NUBEQA (darolutamide) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR NUBEQA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for NUBEQA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03878524 ↗ Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Recruiting Oregon Health and Science University Phase 1 2020-04-01 This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy.
NCT03878524 ↗ Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Recruiting Prospect Creek Foundation Phase 1 2020-04-01 This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy.
NCT03878524 ↗ Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Recruiting OHSU Knight Cancer Institute Phase 1 2020-04-01 This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for NUBEQA

Condition Name

Condition Name for NUBEQA
Intervention Trials
Prostate Cancer 5
Metastatic Prostate Cancer 4
Metastatic Castration-resistant Prostate Cancer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for NUBEQA
Intervention Trials
Prostatic Neoplasms 10
Carcinoma 2
Adenocarcinoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for NUBEQA

Trials by Country

Trials by Country for NUBEQA
Location Trials
United States 52
Brazil 4
Canada 1
United Kingdom 1
Australia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for NUBEQA
Location Trials
South Carolina 3
California 3
Massachusetts 3
New York 2
Oregon 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for NUBEQA

Clinical Trial Phase

Clinical Trial Phase for NUBEQA
Clinical Trial Phase Trials
Phase 3 4
Phase 2 5
Phase 1/Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for NUBEQA
Clinical Trial Phase Trials
Not yet recruiting 6
Recruiting 5
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for NUBEQA

Sponsor Name

Sponsor Name for NUBEQA
Sponsor Trials
Bayer 7
National Cancer Institute (NCI) 2
Prospect Creek Foundation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for NUBEQA
Sponsor Trials
Other 14
Industry 10
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.